Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should stroke patients with mild or improving symptoms receive tissue plasminogen activator therapy?

Nature Clinical Practice Neurology volume 2, pages 354–355 (2006)Cite this article

boxed-textSmith EE et al. (2005) Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 36: 2497–2499

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Adams H et al. (2005) Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 36: 916–923

    Article  Google Scholar 

  2. Barber PA et al. (2001) Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56: 1015–1020

    Article  CAS  Google Scholar 

  3. National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group (2005) Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med 46: 243–252

  4. Hack W et al. (2003) European Stroke Initiative recommendations for stroke management—update 2003. Cerebrovasc Dis 16: 311–337

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Director for Clinical Trials at the National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA

    John R Marler

Authors
  1. John R Marler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John R Marler.

Ethics declarations

Competing interests

J Marler was the project leader for the NINDS tPA Stroke Trial.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marler, J. Should stroke patients with mild or improving symptoms receive tissue plasminogen activator therapy?. Nat Rev Neurol 2, 354–355 (2006). https://doi.org/10.1038/ncpneuro0215

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0215

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing